Several risk factors of ICIs-associated AKI have been reported recently, including the concurrent drugs of proton pump inhibitors (PPIs), angiotensin-converting enzyme inhibitors (ACEIs)/ angiotensin receptor blockers (ARBs) or diuretics, combination therapy with different ICIs, use of ipilimumab or pembrolizumab, coexisting chronic kidney disease (CKD) or low estimated glomerular filtration rate(eGFR), hypertension, the combination of other irAEs and so on [3–5, 9–14]. The gene discussed is ACE; the disease is chronic kidney disease.